ERBB2 and gastric cancer: The phase III ToGA trial established the addition of trastuzumab (a humanized monoclonal antibody that targets HER2) to chemotherapy in advanced HER2‐positive GC based on the improved median OS (16.0 vs. 11.8 months).9